Pituitary Disorders

Research Paper Reviews JFK's Chronic Health Issues

By July 14, 2017

A new review published in the Journal of Neurosurgery: Spine details the health issues that troubled JFK the most, specifically his back. His low-back pain was instigated by a football injury sustained while he was at Harvard in 1937. An orthopedic spine specialist diagnosed him in 1940 with a "very unstable lumbosacral joint".

FDA Approves Triptodur for Central Precocious Puberty

By June 30, 2017

This marks the first gonadotropin-releasing hormone (GnRH) agonist approved for dosing once every 6 months for CPP.

Certain Sandostatin Strengths Discontinued

By May 01, 2017

The decision to discontinue Sandostatin 200mcg and 1000mcg is not due to manufacturing, product quality, safety, or efficacy concerns, according to the Company.

Endocrine Hypertension Screening Statement Released

By April 07, 2017

The Task Force that authored the Society's statement aimed to review the different forms of endocrine hypertension, focusing on prevalence, clinical presentation, recommendations on when to perform case detection testing, and available case-detection tests.

New Guideline on Hypothalamic Amenorrhea Released

By March 23, 2017

Hypothalamic amenorrhea occurs when the hypothalamus slows or stops releasing GnRH, a hormone that controls the menstrual cycle. It can increase the risk of other health issues such as delayed puberty in adolescents and infertility in female adults.

New Guidelines Issued on Treating Children with Growth Failure

January 25, 2017

The Drug and Therapeutics, and Ethics Committees of the Pediatric Endocrine Society have updated the 2003 guideline for growth hormone and insulin-like growth factor-I (IGF-I) treatment in children and adolescents.

Researchers ID Gene Associated With Addison's Disease

November 08, 2016

BACH2 is a major risk locus for Addison's disease, according to a study published online in the Journal of Internal Medicine.

Ophthalmic Steroid Use Tied to Cushing's Sx Onset in 4-Year Old

April 08, 2016

In a case report published online April 7 in Pediatrics, iatrogenic Cushing's syndrome (ICS) is described in an infant following intranasal usage of dexamethasone ophthalmic solution.

Adding Aromatase Inhibitors to Growth Hormone May Boost Boys' Height

By April 04, 2016

Use of aromatase inhibitors for up to 3 years in combination with growth hormone may be an effective and safe option to help very short adolescent boys grow taller, a study presented at ENDO 2016 has found.

FDA: Major Labeling Changes for Opioid Pain Meds

By March 22, 2016

The Food and Drug Administration (FDA) announced it is requiring class-wide safety labeling changes for all immediate-release (IR) opioid pain medicines.

More Increlex Coming Soon

By October 02, 2015

Ipsen announced that in collaboration with the Food and Drug Administration (FDA), it is releasing an additional batch of Increlex (mecasermin [rDNA origin]).

First Study on Transgender Youth Tx Outcomes Starting Soon

By August 18, 2015

The first study in the United States to investigate the long-term outcomes of medical treatment for transgender youth is set to begin in the near future after having been awarded $5.7 million by the National Institutes of Health (NIH).

New FlexPro PenMate Hides Needle During Injection

By July 16, 2015

Novo Nordisk announced that the Food and Drug Administration (FDA) has approved FlexPro PenMate, which is intended for patients who use Norditropin (somatropin [rDNA origin]) FlexPro 5mg, 10mg, and 15mg pens and prefer hidden needles during their injection.

<i>IGF2</i> Variant Can Affect Prenatal, Postnatal Growth

July 09, 2015

An IGF2 variant (c.191C→A, p.Ser64Ter) affects postnatal as well as prenatal growth among those who have inherited the variant through paternal transmission, according to a report published in the New England Journal of Medicine.

Chiasma Submits Octreotide NDA for Acromegaly

By June 16, 2015

Chiasma announced that it has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for octreotide capsules for the maintenance treatment of adults with acromegaly.

AANS: Surgeon Volume Affects Costs in Pituitary Tumor Care

May 06, 2015

For patients with transsphenoidal pituitary tumors, hospital charges, costs, and length of stay are increased with lower-volume surgeons, according to a study presented at the annual meeting of the American Association of Neurological Surgeons.

Serious ADRs Discovered With Hyperprolactinemia Tx in Study

April 01, 2015

Serious adverse drug reactions (ADRs) can occur after bromocriptine use in lactation inhibition, most of which could be avoided, according to a new study.

Ferring to Launch Pediatric Endo Products Zomacton and Zoma-Jet Soon

By March 31, 2015

Ferring announced that the FDA has approved the name changes of its newly acquired products to be marketed as Zomacton (somatropin [rDNA origin]; formerly Tev-Tropin) for injection, and the needle-free delivery system as Zoma-Jet (formerly Tjet).

Ipsen Continues to Resupply Increlex

By March 02, 2015

Ipsen, in collaboration with the FDA is releasing a third batch of Increlex (mecasermin [rDNA origin]), since the initial resumption of product supply in May 2014.

New Norditropin FlexPro Strength Approved

By January 27, 2015

Novo Nordisk announced that the Food and Drug Administration (FDA) has approved a new 30mg/3.0mL strength of Norditropin (somatropin [rDNA origin] injection) FlexPro pen.

The Effects of Risperidone on Prolactin Levels in Children

By December 17, 2014

According to a new study, an increase in serum PRL levels with risperidone therapy could be related not just to the drug and its dosage, but also to sex, pubertal stage, psychiatric disease, and associated autoimmune disorders.

Somatuline Depot Gains New Antitumor Indication

By December 17, 2014

The Food and Drug Administration (FDA) has approved Somatuline Depot (lanreotide; Ipsen Biopharmaceuticals) injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults with unresectable, well or moderately differentiated, locally advanced or metastatic disease to improve progression-free survival.

Signifor LAR Approved for Acromegaly

December 16, 2014

Novartis announced that the Food and Drug Administration (FDA) has approved Signifor LAR (pasireotide diaspartate long-acting release) injectable suspension for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option.

GPR101 Gene Linked to Gigantism in Children

December 04, 2014

In some patients with gigantism, scientists have discovered a duplication of a short stretch of the X chromosome.

Acromegaly Diagnosis, Management Guideline Developed

November 10, 2014

Recommendations have been developed for the diagnosis and management of acromegaly.

Obesity, Endocrine Disruptors Linked to Early Puberty

September 23, 2014

In a recent opinion article, Dr. Laurence Steinberg describes the association between the obesity rate among children in the U.S. and the falling age of the onset of puberty.

Second Increlex Batch Available in September

August 26, 2014

Ipsen announced its second resupply of Increlex (mecasermin [rDNA origin]) injection will be available in September 2014.

Growth Hormone Tx in Childhood Tied to Later Stroke Risk

August 14, 2014

There is a strong relationship between growth hormone (GH) treatment during childhood and subsequent hemorrhagic stroke.

Tesamorelin Cuts Abdominal Fat in HIV Patients

July 22, 2014

For HIV-infected patients with abdominal fat accumulation, the growth hormone-releasing hormone analog tesamorelin is associated with reductions in visceral fat and modest reductions in liver fat.

Somatuline Depot sNDA Submitted for GEP-NETs

July 01, 2014

Ipsen Biopharmaceuticals announced that it has submitted a supplemental New Drug Application (sNDA) to the FDA for Somatuline Depot 120mg injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).